Kathleen A Clouse

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. pmc Cell-type specific requirements for thiol/disulfide exchange during HIV-1 entry and infection
    Tzanko S Stantchev
    Laboratory of Cell Biology, Division of Monoclonal Antibodies, U S Food and Drug Administration, Bethesda, MD 20892, USA
    Retrovirology 9:97. 2012
  2. ncbi request reprint Selective side-chain modification of cysteine and arginine residues blocks pathogenic activity of HIV-1-Tat functional peptides
    Krishnakumar Devadas
    Immunopathogenesis Section, Laboratory of Molecular Virology, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike HFM 315, Rockville, MD 20852 1448, USA
    Peptides 27:611-21. 2006
  3. ncbi request reprint Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection
    Krishnakumar Devadas
    Immunopathogenesis Section, Laboratory of Molecular Virology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, United States
    Peptides 28:496-504. 2007
  4. pmc Heme oxygenase-1 induction alters chemokine regulation and ameliorates human immunodeficiency virus-type-1 infection in lipopolysaccharide-stimulated macrophages
    Zhao Hua Zhou
    Division of Monoclonal Antibodies, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA
    Biochem Biophys Res Commun 435:373-7. 2013
  5. ncbi request reprint Recent advances in understanding the molecular mechanisms of HIV-1 entry and fusion: revisiting current targets and considering new options for therapeutic intervention
    Ingrid Markovic
    Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892 USA
    Curr HIV Res 2:223-34. 2004
  6. pmc APOBEC3G-independent reduction in virion infectivity during long-term HIV-1 replication in terminally differentiated macrophages
    Eri Miyagi
    Laboratory of Molecular Microbiology, Viral Biochemistry Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 0460, USA
    Virology 379:266-74. 2008
  7. ncbi request reprint Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry
    Ingrid Markovic
    Center for Drug Evaluation and Research, Food and Drug Adminiatration, Bethesda, MD, USA
    Blood 103:1586-94. 2004
  8. ncbi request reprint Mechanisms for macrophage-mediated HIV-1 induction
    Krishnakumar Devadas
    Immunopathogenesis Section, Laboratory of Molecular Virology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    J Immunol 173:6735-44. 2004
  9. pmc beta-Estradiol attenuates the anti-HIV-1 efficacy of Stavudine (D4T) in primary PBL
    Mingjie Zhang
    Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA
    Retrovirology 5:82. 2008
  10. doi request reprint Considerations for the development of therapeutic monoclonal antibodies
    Patrick G Swann
    Division of Monoclonal Antibodies, Center for Drugs Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Curr Opin Immunol 20:493-9. 2008

Collaborators

Detail Information

Publications10

  1. pmc Cell-type specific requirements for thiol/disulfide exchange during HIV-1 entry and infection
    Tzanko S Stantchev
    Laboratory of Cell Biology, Division of Monoclonal Antibodies, U S Food and Drug Administration, Bethesda, MD 20892, USA
    Retrovirology 9:97. 2012
    ..There is also ambiguity about which disulfide isomerases/reductases play a major role in HIV-1 entry, as protein disulfide isomerase (PDI) and/or thioredoxin (Trx) have emerged as the two enzymes most often implicated in this process...
  2. ncbi request reprint Selective side-chain modification of cysteine and arginine residues blocks pathogenic activity of HIV-1-Tat functional peptides
    Krishnakumar Devadas
    Immunopathogenesis Section, Laboratory of Molecular Virology, Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike HFM 315, Rockville, MD 20852 1448, USA
    Peptides 27:611-21. 2006
    ....
  3. ncbi request reprint Antibodies against a multiple-peptide conjugate comprising chemically modified human immunodeficiency virus type-1 functional Tat peptides inhibit infection
    Krishnakumar Devadas
    Immunopathogenesis Section, Laboratory of Molecular Virology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, United States
    Peptides 28:496-504. 2007
    ..The HIV-1-Tat-MPC, therefore, has potential for the development of a safe, effective, and economical therapeutic vaccine to reduce the progression of HIV infection...
  4. pmc Heme oxygenase-1 induction alters chemokine regulation and ameliorates human immunodeficiency virus-type-1 infection in lipopolysaccharide-stimulated macrophages
    Zhao Hua Zhou
    Division of Monoclonal Antibodies, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, MD, USA
    Biochem Biophys Res Commun 435:373-7. 2013
    ..These results identify a novel role for HO-1 in the modulation of host immune response against HIV infection of MDM...
  5. ncbi request reprint Recent advances in understanding the molecular mechanisms of HIV-1 entry and fusion: revisiting current targets and considering new options for therapeutic intervention
    Ingrid Markovic
    Division of Monoclonal Antibodies, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892 USA
    Curr HIV Res 2:223-34. 2004
    ....
  6. pmc APOBEC3G-independent reduction in virion infectivity during long-term HIV-1 replication in terminally differentiated macrophages
    Eri Miyagi
    Laboratory of Molecular Microbiology, Viral Biochemistry Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 0460, USA
    Virology 379:266-74. 2008
    ..Thus, the loss of infectivity of HIV-1 viruses produced from long-term infected primary macrophages is due to an APO3G-independent mechanism...
  7. ncbi request reprint Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry
    Ingrid Markovic
    Center for Drug Evaluation and Research, Food and Drug Adminiatration, Bethesda, MD, USA
    Blood 103:1586-94. 2004
    ....
  8. ncbi request reprint Mechanisms for macrophage-mediated HIV-1 induction
    Krishnakumar Devadas
    Immunopathogenesis Section, Laboratory of Molecular Virology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    J Immunol 173:6735-44. 2004
    ..These results provide a mechanism by which macrophages induce HIV-1 replication in latently infected cells...
  9. pmc beta-Estradiol attenuates the anti-HIV-1 efficacy of Stavudine (D4T) in primary PBL
    Mingjie Zhang
    Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA
    Retrovirology 5:82. 2008
    ..Recent work suggests there are gender effects in HIV/AIDS progression. Here we ask whether the sex steroid hormone beta-estradiol affects the replication of HIV-1 or the efficacy of a common anti-retroviral drug, Stavudine (D4T)...
  10. doi request reprint Considerations for the development of therapeutic monoclonal antibodies
    Patrick G Swann
    Division of Monoclonal Antibodies, Center for Drugs Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA
    Curr Opin Immunol 20:493-9. 2008
    ..Advances in product characterization tools, immunogenicity assessments, and other bioanalytical assays can be used to better understand product performance and facilitate development...